Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | artículo de revisión biblioteca |
Language: | English |
Published: |
Multidisciplinary Digital Publishing Institute
2020-12-04
|
Subjects: | Marine natural products, Marine drugs, Anticancer, Drug discovery, Clinical pipeline, |
Online Access: | http://hdl.handle.net/10261/224408 http://dx.doi.org/10.13039/501100000921 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100001871 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-ipna-es-10261-224408 |
---|---|
record_format |
koha |
spelling |
dig-ipna-es-10261-2244082021-12-28T16:53:08Z Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes Barreca, Marilia Spanò, Virginia Montalbano, Alessandra Cueto, Mercedes Díaz Marrero, Ana R. Deniz, Irem Erdoğan, Ayşegül Lukić Bilela, Lada Moulin, Corentin Taffin-de-Givenchy, Elisabeth Spriano, Filippo Perale, Giuseppe Mehiri, Mohamed Rotter, Ana Thomas, Olivier P. Barraja, Paola Gaudêncio, Susana P. Bertoni, Francesco European Cooperation in Science and Technology Fundação para a Ciência e a Tecnologia (Portugal) Slovenian Research Agency Ministerio de Ciencia e Innovación (España) Cabildo de Tenerife Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use. This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST (European Cooperation in Science and Technology) programme. This work was partially supported by the Applied Molecular Biosciences Unit-UCIBIO (UID/Multi/04378/2019), financed by national funds from FCT/MCTES. Additionally, support was received from the FCT/MCTES through grant IF/00700/2014 (to SPG); the Slovenian Research Agency research core funding P1-0245 (to AR); TÜB˙ITAK grant number 216Z167 (to AE); the Ministerio de Ciencia e Innovación (grant RTA 2015-00010-C03-02) (to MC); the Agustin de Betancourt Programme (Cabildo de Tenerife, TFinnova Programme supported by MEDI and FDCAN funds) (to ARDM); the MetaboCell project of Canceropôle Provence-Alpes-Côte d’Azur and the Provence-Alpes-Côte d’Azur Region (to MM). This project (to OPT, Grant-Aid Agreements No. PBA/MB/16/01 and PDOC/19/02/01) was carried out with the support of the Marine Institute and funded under the Marine Research Programme by the Irish Government. Peer reviewed 2020-12-04T10:55:28Z 2020-12-04T10:55:28Z 2020-12-04 artículo de revisión http://purl.org/coar/resource_type/c_dcae04bc Marine Drugs 18, 619: 1-28 (2020) http://hdl.handle.net/10261/224408 10.3390/md18120619 1660-3397 http://dx.doi.org/10.13039/501100000921 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100001871 33291602 en Publisher's version https://doi.org/10.3390/md18120619 Sí open Multidisciplinary Digital Publishing Institute |
institution |
IPNA ES |
collection |
DSpace |
country |
España |
countrycode |
ES |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-ipna-es |
tag |
biblioteca |
region |
Europa del Sur |
libraryname |
Biblioteca del IPNA España |
language |
English |
topic |
Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline |
spellingShingle |
Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline Barreca, Marilia Spanò, Virginia Montalbano, Alessandra Cueto, Mercedes Díaz Marrero, Ana R. Deniz, Irem Erdoğan, Ayşegül Lukić Bilela, Lada Moulin, Corentin Taffin-de-Givenchy, Elisabeth Spriano, Filippo Perale, Giuseppe Mehiri, Mohamed Rotter, Ana Thomas, Olivier P. Barraja, Paola Gaudêncio, Susana P. Bertoni, Francesco Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
description |
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use. |
author2 |
European Cooperation in Science and Technology |
author_facet |
European Cooperation in Science and Technology Barreca, Marilia Spanò, Virginia Montalbano, Alessandra Cueto, Mercedes Díaz Marrero, Ana R. Deniz, Irem Erdoğan, Ayşegül Lukić Bilela, Lada Moulin, Corentin Taffin-de-Givenchy, Elisabeth Spriano, Filippo Perale, Giuseppe Mehiri, Mohamed Rotter, Ana Thomas, Olivier P. Barraja, Paola Gaudêncio, Susana P. Bertoni, Francesco |
format |
artículo de revisión |
topic_facet |
Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline |
author |
Barreca, Marilia Spanò, Virginia Montalbano, Alessandra Cueto, Mercedes Díaz Marrero, Ana R. Deniz, Irem Erdoğan, Ayşegül Lukić Bilela, Lada Moulin, Corentin Taffin-de-Givenchy, Elisabeth Spriano, Filippo Perale, Giuseppe Mehiri, Mohamed Rotter, Ana Thomas, Olivier P. Barraja, Paola Gaudêncio, Susana P. Bertoni, Francesco |
author_sort |
Barreca, Marilia |
title |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
title_short |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
title_full |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
title_fullStr |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
title_full_unstemmed |
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
title_sort |
marine anticancer agents: an overview with a particular focus on their chemical classes |
publisher |
Multidisciplinary Digital Publishing Institute |
publishDate |
2020-12-04 |
url |
http://hdl.handle.net/10261/224408 http://dx.doi.org/10.13039/501100000921 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100001871 |
work_keys_str_mv |
AT barrecamarilia marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT spanovirginia marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT montalbanoalessandra marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT cuetomercedes marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT diazmarreroanar marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT denizirem marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT erdoganaysegul marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT lukicbilelalada marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT moulincorentin marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT taffindegivenchyelisabeth marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT sprianofilippo marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT peralegiuseppe marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT mehirimohamed marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT rotterana marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT thomasolivierp marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT barrajapaola marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT gaudenciosusanap marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses AT bertonifrancesco marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses |
_version_ |
1777669880688934912 |